Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 1, 2019
Reporting Period: Event date of April 1, 2019
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report addresses a regulatory compliance event rather than financial performance.
Material Changes
On April 1, 2019, The Nasdaq Stock Market LLC confirmed that the Company has regained compliance with applicable listing requirements on the Nasdaq Capital Market. Specifically, the Company met the minimum 300 round lot shareholder requirement for initial listing under Listing Rule 5505(a)(3).
Outlook, Risks, and Management Commentary
Management Commentary: The determination by Nasdaq resolves previously disclosed proceedings regarding the round lot holders of the Company's Class A common stock. Nasdaq has confirmed that the matter is now closed.
Risks and Contingencies: The filing indicates the resolution of a prior risk related to potential delisting due to insufficient round lot shareholders.
Key Facts for Investor Verification
- Nasdaq confirmed the Company regained compliance with listing requirements on April 1, 2019.
- The specific requirement met was the minimum 300 round lot shareholder threshold.
- Previous Nasdaq proceedings regarding Class A common stock round lot holders are officially closed.
- No financial data or forward-looking guidance is included in this specific filing.